Hinge Bio Presents Preclinical Data from its GEM-DIMER Program Targeting B Cell Depletion at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
BURLINGAME, Calif. April 8, 2024 /PRNewswire/ -- Hinge Bio, Inc., a privately-held biotechnology company, today announced that Daniel Capon , Ph.D., Chief Scientific Officer, and Juha Punnonen, M.D., Ph.D., Chief Development Officer, are presenting data from the company's GEM-DIMER program targeting B cell depletion at this year's American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. "Hinge Bio is addressing areas of significant unmet medical need with its revolutionary GEM-DIMER platform, which uses topological engineering to combine the most desirable properties of multiple clinically relevant antibodies into a single molecule with dramatically improved activity, while retaining the robust stability and manufacturability of conventional antibodies," said Dr. Capon. Dr. Punnonen added, "This encouraging preclinical data supports advancing its GEM-DIMER candidate targeting CD19, CD20, and Fc gamma receptors as quickly as possible to clinical investigatio
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Investors in Roche Holding (VTX:ROG) have unfortunately lost 18% over the last three years [Yahoo! Finance]Yahoo! Finance
- Managing Total Cost of Care is a Top Goal but Access to Reliable Data is Challenging, the Latest Trends in Specialty Drug Benefits Report by Pharmaceutical Strategies Group (PSG) Found [Yahoo! Finance]Yahoo! Finance
- Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab) for the Treatment of Several Forms of HER2-Overexpressing Cancer [Yahoo! Finance]Yahoo! Finance
- Bonum Therapeutics to Present on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference [Yahoo! Finance]Yahoo! Finance
- Alentis Appoints Alberto Toso Chief Scientific Officer [Yahoo! Finance]Yahoo! Finance